Amylyx Pharmaceuticals (AMLX) Change in Acquisitions & Divestments (2022 - 2026)

Amylyx Pharmaceuticals' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $60.0 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments changed 0.0% year-over-year to $60.0 million; the TTM figure through Mar 2026 stood at $246.0 million (down 25.45% YoY), while the FY2025 annual figure was $246.0 million, down 28.49% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $60.0 million, roughly flat from $60.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $147.9 million in Q4 2023, with the low at $24.9 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $64.0 million (2025), against an average of $72.0 million.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments soared 335.06% in 2023, then sank 56.06% in 2024.
• Amylyx Pharmaceuticals' Change in Acquisitions & Divestments stood at $34.0 million in 2022, then jumped by 335.06% to $147.9 million in 2023, then tumbled by 56.06% to $65.0 million in 2024, then slipped by 7.69% to $60.0 million in 2025, then changed by 0.0% to $60.0 million in 2026.
• Business Quant data shows AMLX's Change in Acquisitions & Divestments at $60.0 million in Q1 2026, $60.0 million in Q4 2025, and $64.0 million in Q3 2025.